SignalEU/UK
Bayer: Turnaround Is Gaining Momentum, But Debt Remains A Risk
Bayer turnaround momentum offset by debt risk, per headline.
Context
What happened: A Seeking Alpha analyst reiterated a long-term Buy on Bayer (OTCPK:BAYZF), citing an easing litigation backdrop and a Crop Sciences five-year plan.
Why it matters: The analyst sees litigation risks easing after a major Supreme Court win, with a key settlement decision expected soon that could improve free cash flow, while pharmaceuticals face a patent cliff offset by growth from Nubeqa, Kerendia, asundexian and Beyonttra.
Key numbers: Crop Sciences targets above-market growth and improved free operating cash flow by 2029.
What changed
A Seeking Alpha analyst reiterated a long-term Buy on Bayer (OTCPK:BAYZF), citing an easing litigation backdrop and a Crop Sciences five-year plan.
Why it matters
The analyst sees litigation risks easing after a major Supreme Court win, with a key settlement decision expected soon that could improve free cash flow, while pharmaceuticals face a patent cliff offset by growth from Nubeqa, Kerendia, asundexian and Beyonttra.
Key numbers: Crop Sciences targets above-market growth and improved free operating cash flow by 2029.